Development of selective small molecule MDM2 degraders based on nutlin

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The tumor suppressor protein p53 is crucial for preventing cancer, but its function is often inhibited by murine double minute 2 protein (MDM2) in cancer cells.
• Targeting MDM2 to restore p53 activity is a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

• To develop novel small molecule MDM2 degraders to reactivate the tumor suppressor p53.
• To evaluate the efficacy of these degraders in inhibiting cancer cell proliferation and inducing apoptosis.

Main Methods:

• Design and synthesis of small molecules incorporating MDM2 and cereblon E3 ubiquitin ligase ligands.
• Assessment of MDM2 degradation, p53 reactivation, and anti-proliferative effects in RS4;11 leukemia cells.
• Determination of IC50 values for proliferation inhibition and evaluation of apoptosis induction.

Main Results:

• A superior MDM2 degrader, featuring a nutlin-based ligand and a lenalidomide-based ligand connected by a short linker, was developed.
• This degrader efficiently promoted MDM2 proteolysis at low nanomolar concentrations in RS4;11 leukemia cells.
• The compound inhibited leukemia cell proliferation with an IC50 of 3.2 nM and effectively induced apoptosis.

Conclusions:

• Small molecule MDM2 degraders can effectively reactivate tumor suppressor p53 by promoting MDM2 proteolysis.
• These MDM2 degraders demonstrate significant anti-leukemic activity, highlighting their potential as novel cancer therapeutics.